Search Results for "michigan"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for michigan. Results 41 to 50 of 308 total matches.
In Brief: Zetia and Vytorin: The ENHANCE Study
The Medical Letter on Drugs and Therapeutics • Jan 28, 2008 (Issue 1278)
., University of Michigan Medical School
Lauren K. Schwartz, M.D., Mount Sinai School of Medicine
DRUG ...
An unpublished 2-year randomized study (ENHANCE) on the effect of adding ezetimibe 10 mg to simvastatin 80 mg in 720 patients with heterozygous familial hypercholesterolemia has been in the news recently. About 80% of these patients had previously been treated with statins. The primary endpoint was the change in the intima-media thickness (IMT) of the carotid artery (baseline 0.68 and 0.69 mm); the IMT increased by 0.0111 mm with ezetimibe plus simvastatin and 0.0058 mm with simvastatin 80 mg alone (p=0.29). The ezetimibe- simvastatin combination lowered LDL-C by 58% compared to 41% lowering...
In Brief: Herbal Warning
The Medical Letter on Drugs and Therapeutics • Feb 11, 2008 (Issue 1279)
., University of Michigan Medical School
Lauren K. Schwartz, M.D., Mount Sinai School of Medicine
DRUG ...
The FDA recently advised health care professionals and consumers not to use a number of dietary supplements found to contain the phosphodiesterase-5 inhibitor sildenafil (Viagra) or an analog of the drug (www.fda.gov). Although the effects of sildenafil may be noticeable (in men), the presence of other, possibly more toxic adulterants in dietary supplements may be more difficult or impossible to detect.Other drugs previously found in dietary supplements have included lovastatin (Mevacor, and others), estrogen, alprazolam (Xanax, and others), indomethacin (Indocin, and others) and warfarin...
In Brief: Genetic Test for Carbamazepine-Induced Stevens-Johnson Syndrome
The Medical Letter on Drugs and Therapeutics • Apr 21, 2008 (Issue 1284)
. Dalton, M.D., M.P.H., University of Michigan Medical School
Lauren K. Schwartz, M.D., Mount Sinai School ...
Genetic Test for Carbamazepine-Induced Stevens-Johnson Syndrome Carbamazepine (Tegretol, Carbatrol, Equetro, and others), which is now used to treat not only epilepsy but also trigeminal neuralgia and manic episodes in patients with bipolar disorder,1 is a known cause of Stevens-Johnson syndrome (SJS). The incidence of carbamazepine-induced SJS in countries with mainly white populations is 1 to 6 per 10,000 new users of the drug, but Asian patients have a 10-fold higher incidence of this reaction. An association has been found between the human leukocyte antigen (HLA)-B*1502 allele and...
In Brief: A New Indication for Colesevelam (Welchol)
The Medical Letter on Drugs and Therapeutics • May 05, 2008 (Issue 1285)
of Michigan Medical School
Lauren K. Schwartz, M.D., Mount Sinai School of Medicine
EDITORIAL ASSISTANT: Liz ...
Colesevelam (Welchol - Daiichi Sankyo - Med Lett Drugs Ther 2000; 42:102), a bile-acid sequestrant used to lower LDL cholesterol, has been approved by the FDA as an adjunct to diet and exercise in the treatment of type 2 diabetes. In unpublished studies summarized in the package insert, patients with type 2 diabetes taking metformin (Glucophage, and others), a sulfonylurea or insulin (each as either monotherapy or in combination with other anti-diabetic agents) were given colesevelam 3800 mg per day or placebo; colesevelam significantly reduced glycosylated hemoglobin (A1c) by about 0.5% more...
Correction: Natalizumab (Tysabri) for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
EDITORIAL FELLOWS:
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Lauren K ...
The May 5, 2008 article (Med Lett Drugs Ther 2008; 50:34) on the approval of natalizumab (Tysabri) for treatment of Crohn's disease in the "Adverse Effects" section on page 35 included the statement: "post-marketing hepatotoxicity, sometimes fatal or requiring liver transplantation, has occurred." Actually, no fatal hepatotoxicity or liver transplantation has been reported to date. The FDA warning about post-marketing hepatotoxicity with Tysabri that was the basis for our statement said: "The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is...
Correction: CT Colonography
The Medical Letter on Drugs and Therapeutics • Jan 12, 2009 (Issue 1303)
:
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D. Albert ...
(Med Lett Drugs Ther 2008; 50:94) In Table 1, "Invasive" should be "less" and "more" rather than "no" and "yes" for CT colonography and colonoscopy, respectively. In the conclusion, CT colonography should be changed to "less invasive" rather than "noninvasive".
The Medical Letter - 50th Anniversary
The Medical Letter on Drugs and Therapeutics • Jan 26, 2009 (Issue 1304)
, Pharm.D.
CONTRIBUTING EDITORS:
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School ...
The Medical Letter was founded in 1959 by Arthur Kallet, an engineer, and Dr. Harold Aaron, an internist. In 1932, Kallet had written the book 100,000,000 Guinea Pigs, a best-seller that was partly responsible for the Food and Drug Act of 1938, which required for the first time that new drugs show proof of safety. He was the founding director of Consumers Union and started the publication of Consumer Reports. Dr. Aaron, who became the medical director of Consumer Reports, suggested to Kallet that doctors could use a similar publication to evaluate the new drugs that were coming on the market...
Correction: Vancomycin Dosing and Monitoring
The Medical Letter on Drugs and Therapeutics • Apr 20, 2009 (Issue 1310)
of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
Sandip K. Mukherjee ...
(Med Lett Drugs Ther 2009; 51:25) In the paragraph on dosing, the second-to-last sentence should have said that the new recommendations suggest considering use of an alternative antibiotic when the MIC for the infecting organism is ≥2 mg/L, not >2 mg/L.
Corrections
The Medical Letter on Drugs and Therapeutics • Aug 24, 2009 (Issue 1319)
. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D. Albert Einstein ...
Benzyl Alcohol Lotion for Head Lice (Med Lett Drugs Ther 2009; 51:57) In Table 1, the price for lindane 1% shampoo should be $136.86 (not $3.00). When a Statin Fails (Med Lett Drugs Ther 2009; 51:58) The first sentence should read as follows: "The National Cholesterol Program recommends that LDL-C be lowered to less than 100 mg/dL (2.6 mmol/L) for patients at high risk...." Tapentadol (Nucynta) - A New Analgesic (Med Lett Drugs Ther 2009; 51:61) In table 1, the half-life for tapentadol should be 4 hours (not...
Corrections: Biannual IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis and Golimumab (Simponi) for Inflammatory Arthritis
The Medical Letter on Drugs and Therapeutics • Jul 27, 2009 (Issue 1317)
. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D. Albert Einstein ...
Corrections: Biannual IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis (Med Lett Drugs Ther 2009; 51:49) - The first word of the title should have been Biennial, not Biannual.
Golimumab (Simponi) for Inflammatory Arthritis (Med Lett Drugs Ther 2009; 51:55) - In Table 1 on page 55, the price for certolizumab (Cimzia) should have been $1,341.68 (not $3,136.40).
Golimumab (Simponi) for Inflammatory Arthritis (Med Lett Drugs Ther 2009; 51:55) - In Table 1 on page 55, the price for certolizumab (Cimzia) should have been $1,341.68 (not $3,136.40).